Israeli Weight Loss Pill Company Stock Soars After New CEO Appointment

Epitomee, an Israeli company developing a swallowable pill for weight loss, has seen its stock price surge dramatically on the Tel Aviv Stock Exchange. The company's shares jumped 15% on a recent trading day and over 110% in the past three days. This significant increase occurred without any new company announcements, leading to speculation about the cause.

The surge is largely attributed to the recent appointment of Dolev Refaeli as the new CEO. Refaeli has a proven track record in rehabilitating companies specializing in medical devices. Investors appear to be placing their trust in his ability to unlock the potential of Epitomee's "blue and white" (Israeli-made) pill.

Refaeli acknowledged that Epitomee's primary challenge lies not with the product itself, but with its distribution channels. Despite this, the company's stock has plummeted approximately 90% since its 2021 IPO. Epitomee's product offers an alternative to weight loss injections and medications. It consists of a tiny device encapsulated in a swallowable capsule. Once in the stomach, it absorbs fluids and expands into a rigid structure, applying gentle pressure to the stomach lining to induce a feeling of fullness before eating.

The pill is designed to be taken twice daily, remaining in the stomach for several hours before passing to the intestines, where it disintegrates. This mechanism is a more sophisticated and safer version of earlier gastric balloons, which required invasive procedures for insertion and removal and carried risks of failure. Epitomee's pill has received approval from the U.S. Food and Drug Administration (FDA) following clinical trials demonstrating its efficacy and safety.

Epitomee initially went public with a valuation of NIS 632 million, which later rose to NIS 1 billion after a commercial agreement with Nestle. However, in 2023, Nestle canceled the partnership, citing unmet targets despite the successful FDA trial, leading to a sharp decline in the company's stock. Refaeli stated that Epitomee holds 70 patents and all necessary approvals, including FDA clearance. His goal is to achieve 20,000 to 30,000 new users in the U.S., generating approximately $50 million in sales. He plans to focus on direct-to-consumer marketing via a dedicated app, bypassing previous U.S. distributors. The company aims to capitalize on the growing weight loss market, noting that many users discontinue injectable treatments due to side effects. Epitomee's pill is already available in Israel at Super-Pharm for NIS 890 and is expected to become more affordable through supplementary health insurance plans.